New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:37 EDTNSTGNanoString reports preliminary Q4 revenue about $10.1M, consensus $9.61M.
NanoString anticipates instrument revenue of approximately $5.3M for Q4, representing approximately 112% growth compared to $2.5M for 4Q12. The company's installed base of nCounter Analysis Systems stood at over 180 systems as of the end of 2013. Consumables revenue is anticipated to be approximately $4.4M in Q4, representing approximately 19% growth over the $3.7M reported for 4Q12.
News For NSTG From The Last 14 Days
Check below for free stories on NSTG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
07:34 EDTNSTGNanoString launches nCounter PanCancer Pathways Panel
NanoString Technologies announced the launch of the nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a way for translational researchers to investigate cancer biology across all major cancer pathways. A growing body of research has demonstrated that a pathway-based approach to the analysis of gene expression provides a framework for understanding the changes between the biology of different cancers and cancer subtypes. From a single tube, the PanCancer Pathways Panel simultaneously analyzes of all of the key cancer pathways: PI3K, STAT, MAPK, TGF, Notch, Hedgehog, Wnt, Apoptosis, Cell Cycle, RAS, Chromatin Modification, Transcriptional Regulation and DNA Damage Control. Processing samples on the nCounter Analysis System takes just 15 minutes of hands-on time and generates reproducible data, representing a solution for studying cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use